Artielle ImmunoTherapeutics

Artielle ImmunoTherapeutics is a clinical-stage, venture-backed company developing a novel, first-in-class biologics platform for the treatment of a range of inflammatory and degenerative diseases. Artielle’s initial therapeutic focus is on neuroinflammation and neurodegenerative diseases, including multiple sclerosis (MS), optic neuritis, methamphetamine addiction, and stroke. Other conditions being pursued for additional applications include rheumatoid arthritis (RA), uveitis, age-related macular degeneration (AMD), and celiac disease.